Dan Lemaitre - May 10, 2024 Form 4 Insider Report for GLOBUS MEDICAL INC (GMED)

Role
Director
Signature
/s/ Kelly G. Huller, Attorney-in-Fact
Stock symbol
GMED
Transactions as of
May 10, 2024
Transactions value $
-$1,629,172
Form type
4
Date filed
5/14/2024, 05:16 PM
Previous filing
Jan 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GMED Class A Common Stock Options Exercise $766K +17.5K +162.04% $43.77 28.3K May 10, 2024 Direct
transaction GMED Class A Common Stock Options Exercise $763K +17.5K +61.84% $43.58 45.8K May 10, 2024 Direct
transaction GMED Class A Common Stock Options Exercise $932K +17.5K +38.21% $53.27 63.3K May 10, 2024 Direct
transaction GMED Class A Common Stock Sale -$4.09M -63.3K -100% $64.61 0 May 10, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GMED Stock Option (Right to Buy Class A Common Stock) Options Exercise $0 -17.5K -100% $0.00* 0 May 10, 2024 Class A Common Stock 17.5K $43.77 Direct F2
transaction GMED Stock Option (Right to Buy Class A Common Stock) Options Exercise $0 -17.5K -100% $0.00* 0 May 10, 2024 Class A Common Stock 17.5K $43.58 Direct F3
transaction GMED Stock Option (Right to Buy Class A Common Stock) Options Exercise $0 -17.5K -100% $0.00* 0 May 10, 2024 Class A Common Stock 17.5K $53.27 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.80 to $64.68, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2 These options were granted on January 22, 2018 and are fully vested.
F3 These options were granted on January 22, 2019 and are fully vested.
F4 These options were granted on January 22, 2020 and are fully vested.